Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 13/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 8/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900699 | 0.92 | TBXAS1 (0.53) | TBXAS1TBXA2RAKR1C3PKMMAPK1 | |
| SCHEMBL4903984 | 0.90 | AKR1C3 (0.53) | TBXAS1TBXA2RAKR1C3ALDH1A1 | |
| SCHEMBL4903960 | 0.90 | TBXAS1 (0.57) | TBXAS1TBXA2RAKR1C3PKMMAPK1 | |
| SCHEMBL4905199 | 0.89 | HTT (0.53) | TBXAS1TBXA2RAKR1C3PKMMAPK1 | |
| SCHEMBL4903722 | 0.85 | TBXAS1 (0.56) | TBXAS1TBXA2RAKR1C3MAPK1 | |
| SCHEMBL4900618 | 0.84 | PKM (0.48) | TBXAS1TBXA2RAKR1C3PKMMAPK1 | |
| SCHEMBL4895621 | 0.84 | AKR1C3 (0.53) | TBXA2RAKR1C3ALDH1A1 | |
| SCHEMBL4906257 | 0.84 | ALDH1A1 (0.54) | TBXAS1TBXA2RAKR1C3ALDH1A1 | |
| SCHEMBL4903600 | 0.84 | TBXAS1 (0.55) | TBXAS1TBXA2RAKR1C3PKMMAPK1 | |
| SCHEMBL4904440 | 0.83 | LTA4H (0.47) | TBXAS1TBXA2RAKR1C3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | TBXAS1 271/4885TBXA2R 330/4885AKR1C3 1645/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | TBXAS1 271/4885TBXA2R 330/4885AKR1C3 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.